The Zhitong Finance App learned that Roche (RHHBY.US) plans to launch 20 new drugs to deal with diseases that have brought the greatest burden to society in this decade. The company is seeking to launch its R&D program. Roche said in a report Monday that the company aims to triple the number of patients using its medication between 2020 and 2029. The company is also seeking to increase the success rate of key late-stage clinical trials by about one-fifth. In recent years, the company had trouble overcoming this hurdle before the drug was approved.

After a series of failures with cancer and Alzheimer's medicines, Roche CEO Thomas Schinecker is looking for a new direction. These new targets are the result of Roche's R&D reforms over more than a year. The company is currently seeking to challenge Novo Nordisk (NVO.US) and Lily.US (LLY.US) in the growing weight loss drug market.

Roche said the company's current pharmaceutical product portfolio will last at least until 2027. According to reports, Thomas Schinecker has cut Roche's product pipeline and focused the company on five major categories: cardiovascular disease, ophthalmology, immunology, neurology, cancer, and hematology.